FLUORESTRADIOL (18F)

उत्पाद अवलोकन

About FLUORESTRADIOL (18F)

FLUORESTRADIOL (18F) is a radiopharmaceutical used in positron emission tomography (PET) imaging to assess estrogen receptor activity in breast tissue. The compound contains the radioactive isotope fluorine‑18, which emits positrons that are detected by PET scanners to produce detailed images of hormone receptor distribution. It is administered intravenously under the supervision of a qualified nuclear medicine specialist. The preparation is sterile and pyrogen‑free, ensuring safety for diagnostic procedures. FLUORESTRADIOL (18F) is typically used in conjunction with other imaging modalities to provide comprehensive evaluation of breast cancer lesions and to guide treatment planning. The procedure is non‑invasive and generally well tolerated, with minimal discomfort reported by patients. The imaging results help clinicians determine receptor status, predict therapeutic response, and monitor disease progression or remission.

Key Benefits & Uses

• Provides precise visualization of estrogen receptor expression in breast tissue.
• Assists in selecting appropriate hormone‑based therapies for breast cancer patients.
• Facilitates monitoring of treatment response and disease progression.

Active Ingredient & Action

The active ingredient is fluorestradiol (18F), a fluorine‑18 labeled estradiol analogue. It binds selectively to estrogen receptors, allowing PET scanners to detect receptor density and distribution. The radioactive decay of fluorine‑18 emits positrons that interact with surrounding tissue, producing gamma photons that are captured to generate high‑resolution images. This mechanism enables clinicians to assess receptor status non‑invasively and to tailor therapeutic strategies accordingly.

Important Notes

FLUORESTRADIOL (18F) is a prescription radiopharmaceutical and must be used only in licensed nuclear medicine facilities. The procedure requires careful handling of radioactive material and adherence to radiation safety protocols. Patients should inform their healthcare provider of any pregnancy, breastfeeding, or recent exposure to other radiopharmaceuticals. The imaging study is typically performed within a few hours of injection, and patients may be advised to avoid strenuous activity for a short period afterward. Side effects are uncommon but may include mild injection site discomfort or transient nausea. Always follow the instructions of your nuclear medicine team for optimal safety and diagnostic accuracy.